A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing

WuXi XDC achieves **GMP certification** for its **Singapore manufacturing site** at Tuas Biomedical Park, marking a milestone in its global expansion. The facility now houses a **dual-function production line** for **BCM3 antibody intermediates** and **conjugated drug substances**, supporting the bioconjugate industry. The site’s launch follows a two-year development period since its announcement in **March 2024**.

Sep 2026PR NewswireNews article

WuXi XDC has out-licensed its **WuXiTecan-2 payload-linker technology platform** to **Ona Therapeutics** to accelerate the development of novel antibody-drug conjugates (ADCs). The collaboration leverages WuXi XDC’s proprietary technology, positioning Ona to advance its first-in-class ADC research. WuXi XDC specializes in contract research, development, and manufacturing for bioconjugates, including ADCs.

Sep 2026MorningstarNews article

WuXi XDC acquires TOT Biopharmaceutical International for up to **$357 million** to strengthen its antibody-drug conjugate (ADC) contract development and manufacturing (CDMO) capabilities. The deal involves purchasing **773 million shares** at **HKD 4.00 per share**, a **99% premium** over TOT Bio’s last undisturbed closing price. The transaction is funded internally and aims to expand WuXi XDC’s position in the biopharmaceutical manufacturing sector.

Jan 2026Fineline CubeNews article

WuXi XDC reports a **62.2% year-over-year revenue increase** in the first half of 2025, reaching **RMB 2.7 billion**. Gross profit surged **82.2% YoY** to **RMB 975 million**, with a **36.1% margin**, while adjusted net profit before interest expenses rose **69.6% YoY** to **RMB 733 million**. The company strengthens its position as a global leader in the bioconjugates industry through sustained financial performance and expanding customer base.

Aug 2025PR NewswireNews article